Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Last year, it claimed a $370 million licensing deal with AbbVie for an AAV8 gene therapy candidate RGX-314 for wet age-related macular degeneration (AMD).

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the ...

Engineering students like An Le (left) and Bo Wen (center) work with Professor Truong Nguyen (right) to develop AI tools that ...

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Aims To estimate prevalence, number and incidence of AMD by type in the UK population aged ≥50 years. Methods Age-specific prevalence rates of AMD obtained from a Bayesian meta-analysis of AMD ...

Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for REGENXBIO in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now expects that the ...